Uma Borate
Clinical trials sponsored by Uma Borate, explained in plain language.
-
New drug combo targets Hard-to-Cure leukemia in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The leukemia must have a FLT3 gene mutation plus e…
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
New hope for rare blood cancers: drug combo trial opens
Disease control Recruiting nowThis study tests a new drug called axatilimab, alone or with another drug (azacitidine), for people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. Axatilimab is an antibody that blocks a protein on white blood cells to slow cancer growth. The trial aims…
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Can a common inflammation blocker stop blood cancer before it starts?
Prevention Recruiting nowThis study tests whether canakinumab, a drug that reduces inflammation, can prevent blood cancer in people with CCUS—a condition where blood counts are low and certain gene mutations raise cancer risk. About 110 adults with high-risk CCUS will receive either canakinumab or a plac…
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Prevention
Last updated May 22, 2026 14:01 UTC